Schizophrenia

Taken as monotherapy or together with antidepressants or other mood stabilizers, Invega Sustenna (paliperidone palmitate) reduces relapse in schizoaffective patients.

Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.

According to research published in the Proceedings of the National Academy of Sciences, patients who are sensitive to d-amphetamine have a decreased likelihood of developing ADHD or schizophrenia.

A once-monthly injectable treatment significantly reduces psychiatric hospitalization for schizophrenia compared to daily oral antipsychotics.

Although the first clinical case associating acromegaly with schizophrenia was reported more than 60 years ago, researchers continue to ponder the association between the 2 disorders.

Schizophrenia and bipolar disorder patients have similar interneuron levels, which may provide further clues into the pathology of the mental illnesses, according to research published in the April issue of Schizophrenia Research.

When encouraging and supporting patients to quit smoking, varenicline is unlikely to increase the risk of neuropsychiatric adverse events such as suicide, depression, and aggression, even in patients with pre-existing psychiatric illness.

Functional impairment captured in two brain regions during a simple memory task may serve as a biomarker for schizophrenia.

Among those with mental disorders, left-handed patients are more likely to be diagnosed with psychotic conditions like schizophrenia than mood disorders like depression.

Depot antipsychotic medications for patients with schizophrenia are often associated with improved treatment adherence.

Creating a safer environment for clinicians and patients starts with better formalized reporting of aggressive and violent behavior, and should also include more rigorous screening and assessment for risk markers of violent behavior.

Genotyping and access to more genetic information about patients may allow clinicians to minimize side effects associated with treatment for schizophrenia by choosing antipsychotic agents based on their unique molecular binding profiles and using the lowest effective doses.

Although we have made great advances in understanding the genetic components of psychiatric illness, caution is essential when applying information from genetic testing to the selection of treatment in clinician practice.

Understanding and addressing these disorders can improve the patient's mental health as well as their chronic pain and other comorbid conditions. Incorporating cognitive behavioral therapy and mindfulness-based cognitive therapy into the management of chronic pain has been shown to improve pain outcomes.

New formulation associated with delayed time to impending relapse, as well as improvements on measures of symptom severity and treatment response.

New validated assessment tools allow clinicians to better assess the level of real-life functioning in patients with schizophrenia.

Mental health advocate calls for a multidisciplinary approach to treating patients with severe mental illness.

A poster presented at the American Psychiatric Association 64th Institute on Psychiatric Services examined whether depot medications work better than oral agents in schizophrenia.

Prescription-only Seroquel found in over-the-counter Nurofen packages leading to recall.

A recent study indicates that traumatic brain injury may be linked to an increased risk of developing schizophrenia.

The application approved for testing is for a treatment known as NW-3509, an "add-on therapy" for schizophrenia.

"De novo" mutations are responsible for over 50% of non-hereditary cases of schizophrenia.

The research shows that the mice in the study displayed a brain-wave pattern that has been associated with autism and schizophrenia in human beings.

Two leading schizophrenia medications will have to contend with generic rivals soon, as their patents will be up sometime over the next twelve months.

The PANSS: a long ongoing debate in the psychiatric community revolves around its efficiency due to mathematical properties.

According to an international assembly of scientists, de novo mutations occur more often in schizophrenic patients than in mentally healthy people.

Researchers used a computer model to initiate symptoms of a virtual schizophrenia in order to shed more light on the inner mechanisms of schizophrenic brains.

A 2009 study found that antipsychotic medications and lifestyle factors cannot fully explain the elevated risk for CVD in patients with schizophrenia.

A brain scan that can recognize an individual's thoughts may provide doctors with more definitive diagnoses for Alzheimer's disease and schizophrenia.

New research points to progressive abnormalities in brain development that emerge as vulnerable individuals develop schizophrenia.